Aytu BioScience Enters $2 Billion Testosterone Replacement Market

Aytu BioScience Enters $2 Billion Testosterone Replacement Market
Aytu_BioScience, Inc. (OTCQX: AYTU) is paying $2 million upfront and purchasing $2 million of Acerus Pharmaceuticals Corporation (TSX: ASP) common stock for an exclusive license agreement for the U.S. commercial rights to Natesto® Nasal Gel. Natesto is the first and only nasal formulation of testosterone approved by the U.S. Food and Drug Administration (FDA) as a replacement therapy for men... Read More